Equibles does not estimate personal net worth.
Get an email with a short summary when Alnylam Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALNY alertsThe proxy statement of Alnylam Pharmaceuticals, Inc. reports total compensation of $6,490,500 for Pushkal Garg in fiscal 2025, including a base salary of $767,900. Disclosed compensation is on record for 6 fiscal years. Pushkal Garg has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Alnylam Pharmaceuticals, Inc. on October 29, 2026. Alnylam Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alnylam Pharmaceuticals, Inc. includes Yvonne Greenstreet (CEO and COO), Yvonne L. Greenstreet (CEO, COO and Board Member), Amy W. Schulman (Chairman and Board Member) and 7 others.
“Today, I'll cover why we remain confident in Triton-CM, the rationale behind the enrollment expansion I've referenced this morning, and the progress we're making beyond TTR, particularly with Brzeaux-Saran and Huntington's disease.”
“Thanks, Chris, and welcome everyone to today's roundtable on ALN 6400, which we believe represents a potentially transformative RNA therapeutic for patients living with rear bleeding disorders.”
“Thanks, Chris, and welcome everyone to today's roundtable on ALN 6400, which we believe represents a potentially transformative RNA therapeutic for patients living with rear bleeding disorders.”
“Alnylam undoubtedly has one of the most robust pipelines in biotech, with over 25 clinical programs spanning multiple therapeutic areas across rare, specialty, and prevalent indications, representing a tremendous opportunity to improve patient health and create value in the years ahead.”
Proxy statement
Start not stated–present
Last confirmed April 1, 2024
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Research and Development Officer | $767,900 | $6,490,500 |
| 2024 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Medical Officer | $682,100 | $2,919,190 |
| 2023 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Medical Officer | $656,900 | $3,231,090 |
| 2022 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Medical Officer | $625,000 | $2,900,580 |
| 2021 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Medical Officer | $568,900 | $4,047,990 |
| 2020 | Alnylam Pharmaceuticals, Inc. (ALNY) | Chief Medical Officer and Executive Vice President, Development & Medical Affairs | $553,200 | $2,587,750 |
